Protective effect of valsartan against doxorubicin‐induced cardiotoxicity: Histopathology and metabolomics in vivo study

Doxorubicin (DOX) treatment has been associated with cardiotoxicity. Therefore, it is crucial to search for a therapeutic that can effectively mitigate DOX‐induced cardiotoxicity. This study was conducted to investigate the protective effects of valsartan (VAL) against DOX‐induced cardiotoxicity. Sp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biochemical and molecular toxicology 2021-09, Vol.35 (9), p.n/a
Main Authors: Alhazzani, Khalid, Alotaibi, Moureq R., Alotaibi, Faisal N., Aljerian, Khaldoon, As Sobeai, Homood M., Alhoshani, Ali R., Alanazi, Ahmed Z., Alanazi, Wael A., Alswayyed, Mohammed
Format: Article
Language:English
Subjects:
Amino acids
Apoptosis
Biomarkers
Cardiotoxicity
Creatine
Creatine kinase
Doxorubicin
Fibrosis
Histopathology
In vivo methods and tests
Metabolic pathways
Metabolites
Metabolomics
valsartan
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Doxorubicin (DOX) treatment has been associated with cardiotoxicity. Therefore, it is crucial to search for a therapeutic that can effectively mitigate DOX‐induced cardiotoxicity. This study was conducted to investigate the protective effects of valsartan (VAL) against DOX‐induced cardiotoxicity. Sprague–Dawley rats were divided into four treatment groups: Group I: Control, Group II: VAL (30 mg/kg, ip), Group III: DOX (15 mg/kg, ip), and Group IV: VAL + DOX (30 + 15 mg/kg, ip). All groups were treated every other day for 14 days. Blood was isolated for biochemical and metabolomics studies, and sections of the heart were also analyzed for histopathological and immunohistochemical alterations to detect changes in P53, BAX, BCL‐2, and P62 expression. The combination of VAL + DOX resulted in a marked decrease in cardiac biomarker enzymes (aminotransferase and creatine phosphokinase) compared to DOX monotherapy. In addition, the histopathological examination of the VAL + DOX combination revealed a low percentage of fibrosis and inflammation. Immunohistochemical expression of p53 and BAX was significantly reduced, whereas BCL‐2 expression was significantly increased in the VAL + DOX treatment group compared to DOX monotherapy. Also, the combination of VAL + DOX reverses the negative effect of DOX on nuclear p62 expression. Analysis of serum metabolites showed that DOX monotherapy reduced the number of several amino acids, whereas the combination of VAL + DOX restored these metabolic pathways. This study revealed the potential cardioprotective effect of VAL, which may provide novel and promising approaches for managing cardiotoxicity induced by DOX.
ISSN:1095-6670
1099-0461
DOI:10.1002/jbt.22842